Variable | Description | No. of patients | % of patients | HR | 95% CI | P |
Categoric | ||||||
PSA changes after 6 wk* | Stable | 38 | 31 | 1.00 | ||
Response | 50 | 40 | 0.45 | 0.25–0.78 | 0.005 | |
Progression | 36 | 29 | 1.98 | 1.11–3.52 | 0.01 | |
Gleason score at diagnosis | <8 | 41 | 36 | 1.00 | ||
≥8 | 74 | 64 | 0.83 | 0.51–1.36 | 0.47 | |
M status at diagnosis | M0 | 76 | 66 | 1.00 | ||
M1 | 39 | 34 | 1.16 | 0.70–1.94 | 0.54 | |
Chemotherapy status | Before chemotherapy | 26 | 23 | 1.00 | ||
After chemotherapy | 89 | 77 | 1.08 | 0.65–1.81 | 0.75 | |
Site of metastases | Nonvisceral | 79 | 69 | 1.00 | ||
Visceral | 36 | 31 | 1.97 | 1.17–3.32 | 0.01 | |
ECOG performance status | 0 | 27 | 23 | 1.00 | ||
1 | 79 | 69 | 1.40 | 0.85–2.30 | 0.17 | |
2 | 9 | 8 | 3.54 | 1.36–9.20 | 0.009 | |
Pain status at baseline† | Asymptomatic disease | 42 | 36 | 1.00 | ||
Symptomatic disease | 73 | 64 | 0.68 | 0.42–1.09 | 0.11 | |
Continuous | ||||||
Time since diagnosis (log10 y) | Median, 0.81 | IQR, 0.57–1.05 | 0.34 | 0.14–0.78 | 0.01 | |
PSA (log10 ng/mL) | Median, 2.13 | IQR, 1.54–2.54 | 1.63 | 1.14–2.33 | 0.007 | |
LDH (log10 U/L) | Median, 2.42 | IQR, 2.33–2.54 | 1.03 | 0.29–3.56 | 0.96 | |
tALP (log10 U/L) | Median, 2.08 | IQR, 1.85–2.39 | 0.87 | 0.43–1.76 | 0.68 |
↵* Stable = PSA decline of <30% and <25% increase; response = PSA decline of ≥30%; progression = PSA increase of ≥25%.
↵† Asymptomatic disease = no pain and no opioid use at baseline; symptomatic disease = presence of pain or use of opioids for cancer-related pain at treatment initiation.
ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase; tALP = total alkaline phosphatase.